Cytokines in leprosy, II. Effect of treatment on serum cytokines in leprosy
- 1 October 1998
- journal article
- research article
- Published by Wiley in International Journal of Dermatology
- Vol. 37 (10) , 741-746
- https://doi.org/10.1046/j.1365-4362.1998.00382.x
Abstract
Background Multidrug therapy (MDT) causes a decrease in the bacterial burden in leprosy patients. Does the decrease in the antigenic stimulation of the immune system have an effect on cytokine production? Methods The effect of treatment on serum cytokines was evaluated in 36 leprosy patients and 35 reactional leprosy patients and compared with that in 20 age‐ and sex‐matched healthy individuals. The enzyme‐linked immunosorbent assay (ELISA) technique was used to measure serum levels of interleukin‐2 receptor (IL‐2R), interleukin‐10 (IL‐10), and interleukin‐1beta (IL‐1β) before and after treatment. These cytokines represent T‐helper 1 (TH1), T‐helper 2 (TH2), and macrophage cytokines, respectively. Results The studied serum cytokines were significantly reduced after 1 year of treatment in leprosy patients. The degrees of reduction were significantly positively correlated with a reduction in the bacterial index (BI) and morphologic index (MI). After 1 year of MDT (but not 6 months), paucibacillary (PB) patients showed a significant reduction in all the studied serum cytokines to levels comparable with those of healthy controls. Multibacillary (MB) patients also showed a significant reduction in all the studied serum cytokines, but the levels were still significantly higher than those of healthy controls. Leprosy patients with high levels of serum IL‐1β were more susceptible to the development of reactions after the initiation of treatment. Corticosteroid therapy of reactional patients resulted in a significant reduction in the studied serum cytokines to levels similar or lower than those of nonreactional leprosy patients. The dose of steroids showed a significant positive correlation with the amount of decrease in IL‐1β. Conclusions MDT caused a reduction in serum cytokines correlated with a reduction in the bacterial burden. It is advisable to continue MDT for PB patients for 1 year. Serum IL‐1β levels may have a prognostic value for the susceptibility of leprosy patients to the development of reactions.Keywords
This publication has 14 references indexed in Scilit:
- Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1 beta: a study on IL-6-deficient mice.The Journal of Experimental Medicine, 1996
- The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum LeprosumThe Journal of Infectious Diseases, 1993
- Cytokine Release from Microglia: Differential Inhibition by Pentoxifylline and DexamethasoneThe Journal of Infectious Diseases, 1992
- Serum tumor necrosis factor and interleukin 1 in leprosy and during lepra reactionsClinical Immunology and Immunopathology, 1992
- Dexamethasone inhibition of interleukin 1 beta production by human monocytes. Posttranscriptional mechanisms.Journal of Clinical Investigation, 1988
- Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells.The Journal of Immunology, 1987
- T cell defect in lepromatous leprosy is reversible in vitro in the absence of exogenous growth factors.The Journal of Immunology, 1987
- Detection and characterization of high affinity plasma membrane receptors for human interleukin 1.The Journal of Experimental Medicine, 1985
- Reversal by Interleukin-2 of the T Cell Unresponsiveness of Lepromatous Leprosy to Mycobacterium LepraeImmunological Reviews, 1984
- Dexamethasone-mediated inhibition of human T cell growth factor and gamma-interferon messenger RNA.The Journal of Immunology, 1984